Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel.

Autor: Leleu X; Department of Haematology University Hospital Centre La Miletrie and Inserm Poitiers France., Katodritou E; Department of Haematology Theagenio Cancer Hospital Thessaloniki Greece., Kuehr T; Department of Internal Medicine IV Academic Teaching Hospital Wels-Grieskirchen Wels Austria., Terpos E; Department of Clinical Therapeutics, School of Medicine National and Kapodistrian University of Athens Athens Greece., Caers J; Department of Haematology Liège University Hospital Centre Liège Belgium., Zambello R; Department of Medicine Haematology and Clinical Immunology Branch, University of Padua Padua Italy., Brescianini A; Research and Development Department Amgen (Europe) GmbH Rotkreuz Switzerland., Liang T; Department of Biostatistics Parexel International Taipei Taiwan., Wetten S; Center for Observational Research Amgen Ltd Uxbridge UK., Badelita SN; Department of Hematology Fundeni Clinical Institute Bucharest Romania.
Jazyk: angličtina
Zdroj: EJHaem [EJHaem] 2022 Nov 06; Vol. 4 (1), pp. 174-183. Date of Electronic Publication: 2022 Nov 06 (Print Publication: 2023).
DOI: 10.1002/jha2.595
Abstrakt: Clinical trials have demonstrated the efficacy and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM); however, prospective real-world data are limited. This real-world, prospective, observational study evaluated carfilzomib use, effectiveness and safety in adults with RRMM. Data are presented for a subset of patients ( n  = 383) who received carfilzomib in combination with lenalidomide and dexamethasone (KRd). The overall response rate (ORR) was 83.6% among 360 evaluable patients. Treatment responses were better when KRd was administered at earlier therapy lines than at later lines of therapy (ORR: second line, 85.3%; third line or later, 81.0%). In patients with the anti-CD38 antibody-refractory disease, ORR was higher when KRd was administered earlier than at later therapy lines (second line/third line, 75.0%; fourth line or later, 60.0%). An ORR of 68.1% and 82.0% was achieved in the lenalidomide-refractory and not lenalidomide-refractory subgroups, respectively. KRd was consistently administered per the European label (twice weekly dose of 27 mg/m 2 ) and the median time to discontinuation was 14.6 months. The safety profile of KRd was consistent with previous studies. These real-world data highlight the effectiveness of KRd as a treatment for patients with RRMM, including those with disease refractory to lenalidomide or anti-CD38 antibodies.
Competing Interests: Xavier Leleu received honoraria from Amgen, BMS, CARsgen Therapeutics, Celgene, Gilead, Janssen, Karyopharm Therapeutics, Merck, Oncopeptides, Roche and Takeda. Eirini Katodritou received honoraria and research funding from Amgen and Janssen‐Cilag; held membership on boards of directors or advisory committees for Amgen and Janssen‐Cilag; received expenses and research funding from Genesis Pharma and Takeda; and received research funding from AbbVie and Karyopharm Therapeutics. Thomas Kuehr received consultancy fees and honoraria from Incyte and Janssen; received honoraria and fees to cover travel, accommodation and expenses from Bayer and Lilly; and received honoraria from AbbVie, Amgen, Celgene, Merck, Novartis, Roche and Takeda. Evangelos Terpos received grants, personal fees and non‐financial support from Amgen regarding this work; received grants, personal fees and non‐financial support from Amgen, Celgene/Genesis Pharma, Janssen and Takeda; and received personal fees from AbbVie, BMS, GSK and Novartis, outside the submitted work. Jo Caers received honoraria from Amgen, Celgene, Janssen and Takeda; held membership on boards of directors or advisory committees for Amgen, Celgene, Janssen and Takeda. Renato Zambello held membership on boards of directors or advisory committees for Celgene and Janssen. Alessandra Brescianini is an employee of Amgen and an equity holder. Tony Liang is an employee of Parexel and received funding from Amgen. Sally Wetten was an employee of Amgen and an equity holder at the time of this work. Sorina N. Badelita received consultancy fees, fees to cover travel, accommodation and expenses from Amgen, Janssen and Takeda; and consultancy fees and honoraria from Novartis.
(© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: